Novel disease‑specific and mechanism‑based treatments sharing good evidence of efficacy for migraine have been recently marketed. However, reimbursement by insurers depends on treatment failure with classic anti‑migraine drugs. In this systematic review and meta‑analysis, we aimed to identify and rate the evidence for efficacy of flunarizine, a repurposed, first‑ or second‑line trea…
Flunarizine, a potent calcium channel blocker has been used for more than three decades for the prophylactic management of migraine. Theories suggest that flunarizine may act through multiple mechanisms such as inhibition of cortical spreading depression, neurogenic inflammation and channelopathy. Flunarizine is efficacious in the management of various types of migraines such as common, classic…